Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002163 | 0.86 | OPRM1 (0.46) | OPRM1OPRL1HTTKDM4EPOLB | |
| SCHEMBL2058630 | 0.84 | AR (0.41) | L3MBTL1OPRM1OPRL1ARLMNA | |
| SCHEMBL4004869 | 0.75 | AR (0.53) | AR | |
| SCHEMBL2286375 | 0.72 | METAP2 (0.41) | L3MBTL1OPRK1LMNA | |
| SCHEMBL31128660 | 0.72 | ADAMTS5 (0.36) | L3MBTL1OPRM1ARPOLBSMN1; SMN2 | |
| SCHEMBL12646885 | 0.71 | AR (0.45) | OPRM1OPRL1ARPOLBPLA2G7 | |
| SCHEMBL4002127 | 0.70 | OPRM1 (0.41) | L3MBTL1OPRM1OPRL1KDM4EALDH1A1 | |
| SCHEMBL31128631 | 0.70 | AR (0.38) | OPRM1OPRL1ARSMN1; SMN2ADAMTS5 | |
| SCHEMBL29240310 | 0.69 | LMNA (0.42) | L3MBTL1OPRK1LMNATSHRALDH1A1 | |
| SCHEMBL2285729 | 0.68 | OPRK1 (0.45) | L3MBTL1OPRK1LMNATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791821-B1 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-05 | — | — | EP | disclosed |
| EP-1791821-B1 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-05 | — | — | EP | disclosed |
| CN-101056862-B | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2013-03-13 | — | — | CN | disclosed |
| US-7968580-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968580-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20090215848-A1 | Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) | LANTER JAMES C | 2009-08-27 | — | — | US | disclosed |
| US-20090215848-A1 | Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) | LANTER JAMES C | 2009-08-27 | — | — | US | disclosed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| CN-101056862-A | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-17 | — | — | CN | disclosed |
| EP-1791821-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-06 | — | — | EP | disclosed |
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | disclosed |
| WO-2006031715-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | L3MBTL1 4698/4885OPRK1 199/4885OPRM1 135/4885 |
| US-20090215848-A1 | Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | L3MBTL1 4698/4885OPRK1 199/4885OPRM1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.